Understanding how gut bacteria affect Type 2 Diabetes risk
Official title: Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk
Run by Laval University · NCT04579900 · Data updated 2026-11-12
This study is trying to see how changes in gut bacteria might affect blood sugar control in people with Type 2 Diabetes compared to those without it.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Laval University Academic / other |
| Locations | 1 site (Québec, Quebec) |
| Status | Recruiting |
| Started | February 1, 2021 |
| Main results expected | December 1, 2025 |
| Study ends | December 1, 2025 |
| Registry record updated | March 18, 2025 |
| Trial ID | NCT04579900 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study include individuals diagnosed with Type 2 Diabetes or those who are not diagnosed but are at risk.
✕Probably not a fit
Patients currently taking oral hypoglycemic agents, lipid-lowering, or antihypertensive drugs may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the relationship between gut microbiota and Type 2 Diabetes (T2D) by examining how changes in gut bacteria may influence glucose control and insulin sensitivity. It aims to identify specific bacterial strains that contribute to dysbiosis and potentially disrupt the gut barrier in individuals with T2D. Through endoscopy and duodenal biopsy, researchers will collect samples from both T2D patients and non-T2D individuals to compare microbial signatures and understand their role in metabolic dysfunction.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or managing Type 2 Diabetes by targeting gut microbiota.
How similar studies have gone: Other studies have shown promising results in understanding the role of gut microbiota in metabolic diseases, suggesting that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * T2DB de novo or non T2DB patients Exclusion Criteria: * oral hypoglycemic agents or lipidlowering or antihypertensive drugs
Where it's running
-
INAF, Université Laval
Québec, Quebec, Canada Recruiting
Study contacts
- Principal investigator: André Marette, PhD — Laval University
- Study coordinator: Geneviève Pilon, PhD
- Email: Genevieve.Pilon@criucpq.ulaval.ca
- Phone: 418-656-8711
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acute Blood Flow Restriction Walking in Type 2 Diabetes
This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.
-
Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin
This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.
-
Differentiating heart disease in autoimmune vs. type 2 diabetes
This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.
-
Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses
This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.
-
Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar
This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.
-
Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes
This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.